{
    "clinical_study": {
        "@rank": "16731", 
        "arm_group": [
            {
                "arm_group_label": "Anlotinib hydrochloric capsule", 
                "arm_group_type": "Experimental", 
                "description": "Anlotinib hydrochloric capsule 12mg QD orally and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent"
            }, 
            {
                "arm_group_label": "Placebo Capsule", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo capsule QD orally and it should be continued until disease progression or patients withdrawal of consent"
            }
        ], 
        "brief_summary": {
            "textblock": "1. To reveal  changes of peripheral markers and blood perfusion parameters in vivo tumor\n           in the phase II study of  anlotinib in patients with advanced non-small cell lung\n           cancer.\n\n        2. To clarify the meaning of peripheral markers and blood perfusion parameters in vivo\n           tumor  in predicting the effect of anti-angiogenic therapy."
        }, 
        "brief_title": "To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in the Phase II Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Non-small Cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Pathology diagnosed with advanced NSCLC with measurable lesions;\n\n          2. Have failed for 2 lines of chemotherapy; 3.18-70 years,ECOG PS:0-2,life expectancy of\n             more than 3 months;\n\n        4.Other cytotoxic drugs,radiation therapy,or surgery\u22654 weeks; 5.Main organs function is\n        normal; 6.Women of childbearing age should take contraceptive measures during the study\n        and within 6 months after end.\n\n        Exclusion Criteria:\n\n          1. SCLC(including mixed with NSCLC);\n\n          2. The central cavity of Squamous cell carcinoma and hemoptysis with NSCLC;\n\n          3. Patients failed to use the anti-tumor angiogenesis therapy;\n\n          4. Patients have many influence factors toward oral medications ;\n\n          5. Brain metastases patients accompanied by symptoms or symptom control for less than\n             two months;\n\n          6. Patients with severe and failed to controlled diseases,including: suboptimal blood\n             pressure control;suffering from myocardial ischemia or above grade I myocardial\n             infarction, arrhythmias and Class I heart failure;activity or failure to control\n             severe infections;liver disease such as cirrhosis, decompensated liver disease,\n             chronic active hepatitis;poorly controlled diabetes (FBG>10mmol/L);urine\n             protein\u2265++,etc.\n\n          7. Patients failed to heal wounds or fractures for Long-term;\n\n          8. 4 weeks before enrollment, patients appeared NCI CTC AE grading >1 pulmonary\n             hemorrhage; 4 weeks before enrollment, patients who appeared NCI CTC AE grade> 2 had\n             other parts of the bleeding; patients have a tendency to bleed (e.g active peptic\n             ulcer) or are receiving thrombolytic or anticoagulant therapy such as Warfarin,\n             heparin or its analogues;\n\n          9. Patients occurred venous thromboembolic events within 6 months;\n\n         10. Patients who have HIV-positive or organ transplantation."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "110", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02029209", 
            "org_study_id": "ALTN-03-II 1.2-2"
        }, 
        "intervention": [
            {
                "arm_group_label": "Anlotinib hydrochloric capsule", 
                "description": "Anlotinib hydrochloric capsule 12 mg QD orally\uff0ccontinuous medication for two weeks, then no medication  for one week, three weeks are a cycle scheme.", 
                "intervention_name": "Anlotinib hydrochloric capsule", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo Capsule", 
                "description": "Placebo capsule QD orally,continuous medication for two weeks, then no medication for one week, three weeks are a cycle scheme.", 
                "intervention_name": "Placebo Capsule", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 6, 2014", 
        "location": {
            "contact": {
                "email": "likai5@medmail.com.cn", 
                "last_name": "Li Kai, doctor"
            }, 
            "facility": {
                "address": {
                    "city": "Tianjin", 
                    "country": "China", 
                    "state": "Tianjin", 
                    "zip": "300600"
                }, 
                "name": "20th Floor, Block C, Lake Road, Hexi District, Tianjin Medical University Cancer Institute and Hospital ."
            }, 
            "investigator": {
                "last_name": "Li Kai, doctor", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "email": "likai5@medmail.com.cn", 
            "last_name": "Li Kai, doctor"
        }, 
        "overall_official": {
            "affiliation": "Tianjin Medical University Cancer Institute and Hospital", 
            "last_name": "Li Kai, doctor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "To detect number of  circulating endothelial cell subsets\uff08 total CECs \u3001aCECs\u3001apopCECs, etc.) by Flow Cytometry;", 
                "measure": "Number of circulating endothelial cell subsets\uff08 total CECs \u3001 aCECs\u3001apopCECs, etc.)", 
                "safety_issue": "No", 
                "time_frame": "Different time points before and after treatment of anlotinib,an expected average of 3 weeks"
            }, 
            {
                "description": "To detect the strength of intratumoral blood perfusion index(BV, BF, PS and MTT) by CT perfusion imaging.", 
                "measure": "The strength of intratumoral blood  perfusion index (BV, BF, PS and MTT) .", 
                "safety_issue": "No", 
                "time_frame": "Different time points before and after treatment of anlotinib,an expected average of 3 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02029209"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd", 
        "sponsors": {
            "collaborator": {
                "agency": "Tianjin Medical University Cancer Institute and Hospital", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}